Higher baseline serum PDGFRβ levels increased the risk of poor 90-day outcome in acute ischemic stroke patients receiving intravenous thrombolysis (OR 1.58; 95% CI 1.35-1.85; P<0.001).
Cohort (n=460)
Are higher baseline serum PDGFRβ levels associated with poor functional outcomes at 90 days in patients with acute ischemic stroke receiving intravenous thrombolysis?
Higher baseline serum PDGFRβ levels are associated with an increased risk of poor functional outcomes at 90 days in patients with acute ischemic stroke receiving intravenous thrombolysis.
Estimación del efecto: OR 1.58 (95% CI 1.35-1.85)
valor p: p=<0.001
Abstract Background and aims Blood–brain barrier (BBB) disruption has been implicated in thrombolysis-related complications and poor functional outcomes in acute ischemic stroke (AIS). Platelet-derived growth factor receptor beta (PDGFRβ), involved in BBB integrity, may serve as a prognostic biomarker. We investigated the association between baseline serum PDGFRβ levels and functional outcomes in patients with AIS. Methods In this prospective cohort study, patients with AIS who received intravenous thrombolysis within 4.5h at the hospital-based database between January 2018 and May 2025 were enrolled. Serum samples were collected before thrombolytic therapy. Poor outcome was defined as functional dependence or all-cause death at 90 days (modified Rankin Scale score 2–6). Logistic regression and restricted cubic spline analyses were used to assess associations between serum PDGFRβ levels and outcomes. Results Among 460 patients (mean age 62.18 ± 12.69 years; 29.35% female), 143 (31.08%) had poor outcomes.Both univariable and multivariate analyses showed that higher serum PDGFRβ levels were associated with an increased risk of poor outcome (P 0.001, Odds RatiosOR)=1.64, 95% Confidence Interval CI 1.42–1.89; P 0.001, OR=1.58, 95% CI 1.35–1.85) . A significant shift in the 90-day mRS distribution was observed with serum PDGFRβ levels 3.004 ng/mL (P 0.001). RCS confirmed a nonlinear dose-response relationship between higher Serum PDGFRβ levels and poor outcome at 90 days (P for non-linearity= 0.012). Conclusions Higher serum pre-thrombolytic PDGFRβ level could be a promising predictor of 90-day poor outcome risk after AIS patients receiving IVT. Conflict of interest Zixin Chen: nothing to disclose. Ding Zhang: nothing to disclose. Yamin Wang: nothing to disclose. Yuan Cao: nothing to disclose. Lulu Pei: nothing to disclose. Bo Song: nothing to disclose. Table 1 and Table 2 - belongs to Results Figure 1 - belongs to Conclusions Figure 2 - belongs to Conclusions
Chen et al. (Fri,) conducted a cohort in acute ischemic stroke (AIS) (n=460). baseline serum PDGFRβ levels was evaluated on functional dependence or all-cause death at 90 days (modified Rankin Scale score 2–6) (OR 1.58, 95% CI 1.35-1.85, p=<0.001). Higher baseline serum PDGFRβ levels increased the risk of poor 90-day outcome in acute ischemic stroke patients receiving intravenous thrombolysis (OR 1.58; 95% CI 1.35-1.85; P<0.001).